Enallylpropymal
Enallylpropymal (Narconumal) is a barbiturate derivative developed by Hoffman la Roche in the 1930s.[1] It has sedative and hypnotic effects and is considered to have a moderate abuse potential.[2]
![]() | |
Clinical data | |
---|---|
Other names | Enallylpropymal |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard | 100.015.876 ![]() |
Chemical and physical data | |
Formula | C11H16N2O3 |
Molar mass | 224.260 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
References
- US 2072829, Schnider O, "N-Methyl-5,5-allylisopropylbarbituric acid", issued 2 March 1937, assigned to Hoffmann-La Roche Inc.
- Eddy NB, Halbach H, Isbell H, Seevers MH (1965). "Drug dependence: its significance and characteristics". Bulletin of the World Health Organization. 32 (5): 721–33. PMC 2555251. PMID 5294186.
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids | |
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.